Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

>
13 of 40
<

Dinesh Patel, CEO of Protagonist Therapeutics

Protagonist Therapeutics has been focused in recent years on building up its ranks of partners for its unique platform for discovering peptide drugs, says CEO Dinesh Patel. He's succeeded in landing such deals with Ironwood Pharmaceuticals ($IRWD) in 2011 and extended in December and Zealand Pharma last year. The Menlo Park, CA-based biotech is thinking about building out its own pipeline, which has Patel out talking to investors about a Series B round. The company would like to focus on oral peptide drugs for irritable bowel disease as an internal program.